NewsMV
TG Therapeutics (TGTX) is in focus after Betaville issued an "uncooked" alert on Aug. biopharma company with a market cap between $20 billion and $40 billion may be interested in acquiring the biotech.
Betaville named no buyer, and TG Therapeutics has not confirmed that any discussions are underway. The next confirmable event is a formal statement from either party or the public identification of a named suitor.
The numbers BRIUMVI, TG Therapeutics' multiple sclerosis therapy, generated U.S. revenue of $227.7 million in Q2, a 64% year-over-year gain.
On the strength of that print, management raised the company's 2026 revenue target to approximately $950 million. The company is profitable and actively investing in its commercial buildout and pipeline.
Keep reading